Moving Toward Precision Medicine in Adult Acute Myeloid Leukemia

Moving Toward Precision Medicine in Adult Acute Myeloid Leukemia

Episodes

Specialty:

All

Year:

All

EP. 1: Risk-directed Approaches to AML Therapy

January 10th 2017

EP. 2: CPX-351 for Older Patients with AML

January 10th 2017

EP. 3: MRD Assessment and Consolidation in AML

January 10th 2017

EP. 4: Maintenance Therapy for AML

January 10th 2017

EP. 5: Emerging Role of FLT3 Inhibitors in AML: Midostaurin

January 10th 2017

EP. 6: Quizartinib in AML

January 10th 2017

EP. 7: IDH1/2 inhibitors for AML

January 10th 2017

EP. 8: Vosaroxin/Cytarabine in AML

January 10th 2017

EP. 9: Venetoclax in AML

January 10th 2017

EP. 10: Emerging Therapies for Acute Myeloid Leukemia

January 10th 2017

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management

Datopotamab Druxtecan and ADC Toxicity Management in EGFR-Mutant NSCLC

TP53 Co-Mutations and Prognosis in EGFR-Mutated NSCLC

Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC